Gross-to-net pressure has become one of the defining commercial realities in specialty pharma. According to Hoot’s latest executive briefing, manufacturers gave back an estimated $356 billion in rebates, government discounts, 340B obligations, and chargebacks before net revenue was ever recognized. That number alone changes how commercial leaders think about growth. The challenge is no longer […]
Read more
AI has moved out of the experimental phase in healthcare. It is no longer something teams are exploring on the side. It is now embedded in how organizations think about patient engagement, communication, and scale. But as adoption accelerates, something more subtle is happening beneath the surface. Patients are not just receiving more information. They […]
Read more
Healthcare is entering a new era, and it is not being shaped by innovation alone. It is being shaped by confusion. Patients today are navigating a level of complexity that has never existed before. Specialty therapies are more advanced, treatment pathways are more nuanced, and the volume of information available online is overwhelming. While this […]
Read more
Artificial intelligence is not just another digital tool in healthcare. It is quietly becoming the first place patients go when something feels off, when they receive a diagnosis, or when they are trying to decide what to do next. That shift is changing everything. In Episode 3 of The Patient Experience Podcast, Bob Miglani and […]
Read more
For more than a decade, pharmaceutical leaders have treated gross to net as a pricing problem. The focus has been on rebates, PBMs, formulary positioning, and increasingly complex contracting strategies. Entire teams are dedicated to modeling discount structures and negotiating access. Yet despite all of this effort, the gap between list price and net revenue […]
Read more
The pharmaceutical industry is facing a growing challenge that is quietly undermining both patient outcomes and commercial performance. While scientific innovation has accelerated and therapies have become more targeted and sophisticated, patient understanding has not kept pace. The result is what can only be described as a patient confusion crisis. For decades, pharmaceutical strategy has […]
Read more
Every year, millions of prescriptions are written that patients never start. Some patients never pick up their medication. Others start therapy but stop within weeks. For healthcare systems, pharmaceutical companies, and providers alike, this represents one of the most expensive and preventable failures in modern medicine. In the United States alone, roughly one in four […]
Read more
Today we released a press announcement that addresses something pharma leaders already feel in their forecasts, but rarely quantify directly: Patient dropout is quietly draining $250 billion from the U.S. pharmaceutical market every year. You can read the full announcement here:https://www.prnewswire.com/news-releases/pharma-is-losing-250-billion-to-patient-dropout-heres-how-to-stop-it-302696178.html Not because therapies do not work. Not because innovation has slowed. But because patients […]
Read more
Pharmaceutical brands are delivering extraordinary science to market. Yet an increasing percentage of prescribed patients never initiate therapy. Not because the product does not work.Not because physicians are not prescribing it. But because the moment education leaves the physician’s hands, initiation risk skyrockets. The hidden gap between prescription and start From a brand perspective, the […]
Read more
Listen to Episode 1: Pharma’s Direct to Patient Pivot: What to Expect in 2026 here. The pharmaceutical industry is moving faster than patients can keep up. Therapies are becoming more specialized. Disease education is more complex. Access models are shifting Direct to Patient. At the same time, physician time is shrinking and patients are being […]
Read more